Caribou Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Licensing and other third-party revenue (including zero and $622 from a related party for the three months ended March 31, 2026, and March 31, 2025, respectively) | $2,397 | $2,353 |
| Operating expenses: | ||
| Research and development | 20,611 | 35,531 |
| General and administrative | 8,066 | 9,735 |
| Total operating expenses | 28,677 | 45,266 |
| Loss from operations | (26,280) | (42,913) |
| Other income | ||
| Other income, net | 1,195 | 2,922 |
| Total other income | 1,195 | 2,922 |
| Net loss | (25,085) | (39,991) |
| Other comprehensive loss | ||
| Net unrealized loss on available-for-sale marketable securities, net of tax | (126) | (88) |
| Net comprehensive loss | $(25,211) | $(40,079) |
| Net loss per share, basic and diluted | $(0.26) | $(0.43) |
| Weighted-average common shares outstanding, basic and diluted | 95,861,716 | 92,679,493 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.